X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Groups sound the alarm on administration’s new Part B proposal

By Nicole Longo  |    November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...   Read More

4 things you need to know about the administration’s latest Part B proposal

By Nicole Longo  |    November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....   Read More

PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

By Douglas Petersen  |    November 2, 2018
International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in...   Read More

PhRMA CEO discusses industry’s new approach to DTC television advertising

By Holly Campbell  |    October 17, 2018
PhRMA president and CEO Stephen J. Ubl joined CBS This Morning and MSNBC Live with Ali Velshi to discuss PhRMA member companies’ commitment to providing patients with the information they need to...   Read More

FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies

By Richard Moscicki, M.D.  |    October 16, 2018
The U.S Food and Drug Administration (FDA) plays a critical role in protecting and promoting the health of all Americans. Every day, the FDA does important work to ensure the safety, efficacy and...   Read More

What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising

By Holly Campbell  |    October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...   Read More

Americans want to know more than just the list price of a medicine—and we’re answering their call

By Robert Zirkelbach  |    October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...   Read More

Balancing innovation and competition in the biologics marketplace

By David Korn  |    October 11, 2018
Last month, I presented at the U.S. Food and Drug Administration’s (FDA) Public Hearing on Facilitating Competition and Innovation in the Biological Products Marketplace. The hearing was part of...   Read More

Report: Corporate venture capital is catalyzing groundbreaking biomedical innovation in the United States

By Anne McDonald Pritchett, PhD  |    October 10, 2018
Venture capital is increasingly becoming the growing force for financing biotech and other startups, fueling medical advances in the U.S.  A new report released today from TEConomy, examines the...   Read More

ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation

By Nicole Longo  |    October 9, 2018
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses, detailing how such schemes expose Americans to dangerous counterfeit medicines. The reporter...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates